Segment Information - Schedule of Financial Information by Segment (Details) - USD ($)	3 Months Ended				9 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Segment Reporting Information [Line Items]
Net sales	$ 3,786,000			$ 4,135,000	$ 10,659,000	$ 13,846,000
Gross profit	184,000			(3,078,000)	4,252,000	(572,000)
Direct expenses	16,212,000			35,454,000	92,565,000	113,899,000
Segment contribution	(16,028,000)			(38,532,000)	(88,313,000)	(114,471,000)
Indirect expenses	83,228,000			(32,886,000)	117,289,000	(71,386,000)
Income (loss) from operations	(99,256,000)			(5,646,000)	(205,602,000)	(43,085,000)
Components of other
Change in fair value of contingent consideration liability	0			(33,243,000)	(104,339,000)	(73,441,000)
Change in fair value of contingent stock consideration					(159,000)	415,000
Goodwill impairment	82,714,000	$ 0	$ 29,633,000	0	112,347,000	0
IPR&D impairment	0			0	107,800,000	0
Cell Therapy
Segment Reporting Information [Line Items]
Direct expenses	4,887,000			19,863,000	53,505,000	65,896,000
Segment contribution	(4,887,000)			(19,863,000)	(53,505,000)	(65,896,000)
Components of other
Goodwill impairment	82,714,000				112,347,000
Biobanking
Segment Reporting Information [Line Items]
Net sales	1,427,000			1,405,000	4,062,000	4,061,000
Gross profit	1,029,000			506,000	2,707,000	949,000
Direct expenses	350,000			432,000	780,000	1,314,000
Segment contribution	679,000			74,000	1,927,000	(365,000)
Degenerative Disease
Segment Reporting Information [Line Items]
Net sales	2,359,000			2,730,000	6,597,000	9,785,000
Gross profit	(845,000)			(3,584,000)	1,545,000	(1,521,000)
Direct expenses	1,901,000			3,194,000	6,799,000	7,832,000
Segment contribution	(2,746,000)			(6,778,000)	(5,254,000)	(9,353,000)
Other
Segment Reporting Information [Line Items]
Direct expenses	9,074,000			11,965,000	31,481,000	38,857,000
Segment contribution	(9,074,000)			(11,965,000)	(31,481,000)	(38,857,000)
Indirect expenses	83,228,000			(32,886,000)	117,289,000	(71,386,000)
Components of other
Change in fair value of contingent consideration liability				(33,243,000)	(104,339,000)	(73,441,000)
Change in fair value of contingent stock consideration	(39,000)			(196,000)	(159,000)	415,000
IPR&D impairment					107,800,000
Amortization	553,000			553,000	1,640,000	1,640,000
Total other	$ 83,228,000			$ (32,886,000)	$ 117,289,000	$ (71,386,000)